Genecradle Therapeutics CO.,LTD.
News
News
Follow GeneCradle's progress
Happy Children's Day | Guarding hope and future

2024-06-01

Share:

June is full of life 

In the beautiful promise with the early summer sun

The most beautiful thing about the day is the morning light

The most beautiful time of life is childhood

Childlike innocence shines, hope shines
In love and protection

GeneCradle and the babies witnessed
The miracle of gene therapy


GeneCradle protects hope, hope protects the future



Gene therapy gives children energy to be naughty and active



Currently, children who have received GeneCradleGC301 gene therapy for infantile Pompe disease (IOPD) have been able to stop enzyme replacement therapy and achieved multiple new motor milestones.



Gene therapy gives direction to children's fantastic dreams



Children with spinal muscular atrophy (SMA) who have received GeneCradleGC101 gene therapy have shown varying degrees of improvement in motor skills.




On the eve of Children's Day, the first patient in the world to receive AAV gene therapy for infantile Pompe disease celebrated his 2nd birthday



The children’s small progress is a big surprise

It is the most beautiful medal for our persistence

The children’s sweet smiles and vigor
It is the strongest motivation for us to move forward



The sun is rising, and the basket is full of beautiful things every year

On this day that belongs to the children
May your smiles always be bright

Dreams come true!

Son

child

Festival

quick

happy

HAPPY CHILDREN'S DAY

About GeneCradle

Beijing GeneCradle Technology Co., Ltd. is a national high-tech enterprise with the development of gene therapy drugs mediated by AAV vector delivery technology as its core business. Its mission is to promote China's rare disease gene drugs from basic to clinical and market, benefiting patients and families. The company focuses on the development of gene therapy drugs in the fields of hereditary neuromuscular diseases, genetic metabolic diseases, lysosomal diseases and ophthalmic diseases. By promoting the development and clinical application of rare disease gene drugs, it has a deeper understanding of life and health, and has transitioned gene therapy technologies and products from rare diseases to the treatment and rehabilitation of chronic diseases and other major diseases.